Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system.

Tirzepatide

Dual GIP/GLP-1 receptor agonist39 amino acidsBrand: Mounjaro, Zepbound

AFDA Approved
90
Excellent Credibility
2 cited studies | Evidence level A

Tirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.

Mechanism of Action

Simultaneously activates GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and reducing appetite. The dual agonism provides additive metabolic benefits.

Benefits

  • Up to 22.5% mean body weight loss (SURMOUNT-1)[1]
  • Superior HbA1c reduction vs semaglutide (SURPASS-2)[2]
  • Improved insulin sensitivity[2]
  • Reduced cardiovascular risk factors[2]
Not medical advice - research-reported information only

This content is for informational purposes only and does not constitute medical advice.

Tirzepatide - Dosing in Published Research

Reported routes: Subcutaneous injection
Titrated from 2.5 mg SC weekly, increasing in 2.5 mg increments every 4 weeks to 5, 10, or 15 mg weekly.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Nausea and vomiting[1]
  • Diarrhea[1]
  • Decreased appetite[1]
  • Constipation[1]
  • Injection site reactions[1]

Discuss Tirzepatide with a doctor

Tirzepatide is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.

Get the Provider Checklist

Start with the evidence and provider checklist while routing is offline.

FDA approvedBoard-certified doctorsPrescription if appropriate

PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.

Approved Treatment Routing

Tirzepatide in PeptideScholar's approved-treatment dataset

Tirzepatide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities. Brand names in the current dataset: Mounjaro, Zepbound.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It is not a substitute for checking current prescribing, labeling, payer, or local regulatory details.

Tirzepatide Next Steps

ES selected - using US-first conversion assets
Treatment Hub
Tirzepatide Treatment Guide

Approved product paths, real cost friction, provider routing, and tracker next steps — all in one source-backed hub.

Open treatment hub →

Research & Evidence

Compare Tirzepatide With

References

  1. 1.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med, 2022. "Tirzepatide produced mean weight reductions of 15-22.5% at 72 weeks across dose groups vs 3.1% with placebo" [PMID: 35658024]
  2. 2.Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.. N Engl J Med, 2021. "Tirzepatide at all doses was superior to semaglutide 1 mg for HbA1c reduction and weight loss" [PMID: 34170647]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

GLP-1 Support Essentials

Products to help manage side effects and optimize outcomes during treatment.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Progress Tracking Tools

Monitor weight, body composition, and nutrition to maximize results.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.